Sept 2 \u2014 South Korea’s Alteogen said on Wednesday it has \u200bsigned a deal with Novartis worth up to $3.22 billion, giving the Swiss drugmaker \u200caccess to its technology to make injectable versions of intravenous \u2060drugs.<\/p>\n
Here are the details:<\/p>\n
\u2022 \u200bDrugmakers are increasingly developing \u2060under-the-skin versions of medicines traditionally delivered through \u200cIV infusions \u200cdue to their convenience.<\/p>\n
\u2022 The licensing agreement gives \u2060Novartis multiple options \u2060to gain exclusive rights for Alteogen’s Hybrozyme technology using the company’s ALT-B4 enzyme, also known as berahyaluronidase alfa.<\/p>\n
\u2022 ALT-B4 works by temporarily breaking down hyaluronan, a natural substance found \u200cin the body’s tissue, allowing \u200bmedicines to spread and be absorbed more quickly when injected under the skin.<\/p>\n
\u2022 Alteogen said it would be eligible to receive up to $3.22 billion if Novartis exercises all options and all development and commercial milestones are achieved. \u200bThe figure includes option exercise fees, milestone \u200cpayments and royalties \u200con \u2060future product sales.<\/p>\n
\u2022 This marks Alteogen’s fourth such licensing deal this year.<\/p>\n
\u2022 The ALT-B4 technology is used in the injectable version of Merck’s \u200ctop-selling drug, Keytruda. \u200bThe injection, branded Keytruda \u200cQlex, got FDA \u2060approval last \u200byear.<\/p>\n
(Reporting by Kamal Choudhury in Bengaluru; Editing by Leroy \u200bLeo)<\/p>\n","protected":false},"excerpt":{"rendered":"Sept 2 \u2014 South Korea’s Alteogen said on Wednesday it has \u200bsigned a deal with Novartis worth up…\n","protected":false},"author":2,"featured_media":125953,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[3243,3242,3244,2790,305,1202,206,3246,3247,307,3245,3241,3248,876],"class_list":["post-125952","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-cars","tag-classifieds","tag-homes","tag-jobs","tag-local","tag-news","tag-novartis","tag-radio","tag-salt-lake","tag-sports","tag-television","tag-traffic","tag-utah","tag-weather"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117213093241325682","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/125952","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=125952"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/125952\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/125953"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=125952"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=125952"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=125952"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}